Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial | Synapse
March 3, 2026Open Access
Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial
Key Points
Prevention of secondary infections is the primary aim of the trial protocol, focusing on immune suppression in ICU settings.
The trial involves randomised methods, assessing the role of interferon-gamma in patients with sustained immune suppression.
This protocol targets patients in intensive care units who are at risk for secondary infections due to immune dysregulation.
If successful, the findings may provide insights into new therapeutic approaches for preventing infections in vulnerable populations.